PESQUISA DE SATISFAÇÃO - TOP 10 ONCOLOGY NURSING 2024 Survey

Obrigado por participar do evento TOP 10 ONCOLOGY NURSING
Por favor, complete esta pesquisa de satisfação. Sua opinião é importante e nos ajudará a atender às suas necessidades profissionais para o próximo evento.

Para viabilizar a emissão do seu certificado, por favor, preencha os campos abaixo.

Seus dados de identificação serão desconsiderados para fins de análise de resultados dos feedbacks coletados nesta pesquisa.

	Ruim	Regular	Bom	Excelente	N/D
Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator.	Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Ruim	Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Regular	Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Bom	Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Excelente	Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. N/D
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.	Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Ruim	Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Regular	Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Bom	Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Excelente	Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. N/D
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.	Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Ruim	Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Regular	Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Bom	Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Excelente	Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. N/D
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.	Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Ruim	Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Regular	Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Bom	Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Excelente	Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. N/D
Evaluation of knowledge in oncology about the care of transgender people: A scoping review.	Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Ruim	Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Regular	Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Bom	Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Excelente	Evaluation of knowledge in oncology about the care of transgender people: A scoping review. N/D
Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center.	Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Ruim	Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Regular	Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Bom	Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Excelente	Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. N/D
Health literacy in cancer care: A systematic review.	Health literacy in cancer care: A systematic review. Ruim	Health literacy in cancer care: A systematic review. Regular	Health literacy in cancer care: A systematic review. Bom	Health literacy in cancer care: A systematic review. Excelente	Health literacy in cancer care: A systematic review. N/D
Health-related quality of life the first year after a prostate cancer diagnosis a systematic review.	Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Ruim	Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Regular	Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Bom	Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Excelente	Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. N/D
The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain.	The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Ruim	The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Regular	The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Bom	The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Excelente	The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. N/D
The application and use of artificial intelligence in cancer nursing: A systematic review.	The application and use of artificial intelligence in cancer nursing: A systematic review. Ruim	The application and use of artificial intelligence in cancer nursing: A systematic review. Regular	The application and use of artificial intelligence in cancer nursing: A systematic review. Bom	The application and use of artificial intelligence in cancer nursing: A systematic review. Excelente	The application and use of artificial intelligence in cancer nursing: A systematic review. N/D

Ruim

Regular

Bom

Excelente

N/D

Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator.

Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Ruim

Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Regular

Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Bom

Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. Excelente

Defining the Role and Responsibilities of the Oral Anticancer Medication Nurse Navigator. N/D

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Ruim

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Regular

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Bom

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Excelente

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. N/D

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Ruim

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Regular

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Bom

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Excelente

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. N/D

Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.

Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Ruim

Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Regular

Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Bom

Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. Excelente

Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial. N/D

Evaluation of knowledge in oncology about the care of transgender people: A scoping review.

Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Ruim

Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Regular

Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Bom

Evaluation of knowledge in oncology about the care of transgender people: A scoping review. Excelente

Evaluation of knowledge in oncology about the care of transgender people: A scoping review. N/D

Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center.

Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Ruim

Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Regular

Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Bom

Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Excelente

Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. N/D

Health literacy in cancer care: A systematic review.

Health literacy in cancer care: A systematic review. Ruim

Health literacy in cancer care: A systematic review. Regular

Health literacy in cancer care: A systematic review. Bom

Health literacy in cancer care: A systematic review. Excelente

Health literacy in cancer care: A systematic review. N/D

Health-related quality of life the first year after a prostate cancer diagnosis a systematic review.

Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Ruim

Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Regular

Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Bom

Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. Excelente

Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. N/D

The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain.

The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Ruim

The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Regular

The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Bom

The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. Excelente

The Effects of WeChat-Based Teach-Back Health Education on Patients With Advanced Cancer Pain. N/D

The application and use of artificial intelligence in cancer nursing: A systematic review.

The application and use of artificial intelligence in cancer nursing: A systematic review. Ruim

The application and use of artificial intelligence in cancer nursing: A systematic review. Regular

The application and use of artificial intelligence in cancer nursing: A systematic review. Bom

The application and use of artificial intelligence in cancer nursing: A systematic review. Excelente

The application and use of artificial intelligence in cancer nursing: A systematic review. N/D

PESQUISA DE SATISFAÇÃO - TOP 10 ONCOLOGY NURSING 2024

Question Title

1. Nome Completo (Obrigatório)

Question Title

2. CPF (Obrigatório)

Question Title

3. E-MAIL (Obrigatório)

Question Title

4. Qual é a sua faixa etária? (Obrigatório)

Question Title

5. PROFISSÃO (Obrigatório)

Question Title

6. VOCÊ É ESPECIALISTA EM ONCOLOGIA? (Obrigatório)

Question Title

7. Qual sua área de atuação? (Obrigatório)

Question Title

8. De forma geral, como você classificaria o EVENTO? (Obrigatório)

Question Title

9. Quão organizado foi o EVENTO? (Obrigatório)

Question Title

10. De forma geral, como você avalia a programação científica do EVENTO (Obrigatório)

Question Title

11. Como você avalia as PALESTRAS do Evento?
Caso não tenha assistido selecione a opção N/D (Obrigatório)

Question Title

12. O que poderia ser feito para que as próximas edições dos EVENTO sejam melhores? (Obrigatório)

Question Title

13. Qual a probabilidade de você participar do próximo TOP 10 ONCOLOGY NURSING? (Obrigatório)

Question Title

14. Qual a probabilidade de você recomendar o TOP 10 para um colega? (Obrigatório)

Question Title

15. Escreva aqui seu comentário ou sugestão

PESQUISA DE SATISFAÇÃO - TOP 10 ONCOLOGY NURSING 2024

Question Title

* 1. Nome Completo (Obrigatório)

Question Title

* 2. CPF (Obrigatório)

Question Title

* 3. E-MAIL (Obrigatório)

Question Title

* 4. Qual é a sua faixa etária? (Obrigatório)

Question Title

* 5. PROFISSÃO (Obrigatório)

Question Title

* 6. VOCÊ É ESPECIALISTA EM ONCOLOGIA? (Obrigatório)

Question Title

* 7. Qual sua área de atuação? (Obrigatório)

Question Title

* 8. De forma geral, como você classificaria o EVENTO? (Obrigatório)

Question Title

* 9. Quão organizado foi o EVENTO? (Obrigatório)

Question Title

* 10. De forma geral, como você avalia a programação científica do EVENTO (Obrigatório)

Question Title

* 11. Como você avalia as PALESTRAS do Evento?Caso não tenha assistido selecione a opção N/D (Obrigatório)

Question Title

* 12. O que poderia ser feito para que as próximas edições dos EVENTO sejam melhores? (Obrigatório)

Question Title

* 13. Qual a probabilidade de você participar do próximo TOP 10 ONCOLOGY NURSING? (Obrigatório)

Question Title

* 14. Qual a probabilidade de você recomendar o TOP 10 para um colega? (Obrigatório)

Question Title

* 15. Escreva aqui seu comentário ou sugestão

1. Nome Completo (Obrigatório)

2. CPF (Obrigatório)

3. E-MAIL (Obrigatório)

4. Qual é a sua faixa etária? (Obrigatório)

5. PROFISSÃO (Obrigatório)

6. VOCÊ É ESPECIALISTA EM ONCOLOGIA? (Obrigatório)

7. Qual sua área de atuação? (Obrigatório)

8. De forma geral, como você classificaria o EVENTO? (Obrigatório)

9. Quão organizado foi o EVENTO? (Obrigatório)

10. De forma geral, como você avalia a programação científica do EVENTO (Obrigatório)

11. Como você avalia as PALESTRAS do Evento?
Caso não tenha assistido selecione a opção N/D (Obrigatório)

12. O que poderia ser feito para que as próximas edições dos EVENTO sejam melhores? (Obrigatório)

13. Qual a probabilidade de você participar do próximo TOP 10 ONCOLOGY NURSING? (Obrigatório)

14. Qual a probabilidade de você recomendar o TOP 10 para um colega? (Obrigatório)

15. Escreva aqui seu comentário ou sugestão